ATE273012T1 - Kombinationen von lamivudin und entecavir für behandlung der hepatitis b virus infektion - Google Patents

Kombinationen von lamivudin und entecavir für behandlung der hepatitis b virus infektion

Info

Publication number
ATE273012T1
ATE273012T1 AT00971593T AT00971593T ATE273012T1 AT E273012 T1 ATE273012 T1 AT E273012T1 AT 00971593 T AT00971593 T AT 00971593T AT 00971593 T AT00971593 T AT 00971593T AT E273012 T1 ATE273012 T1 AT E273012T1
Authority
AT
Austria
Prior art keywords
entecavir
lamivudine
hepatitis
combinations
treatment
Prior art date
Application number
AT00971593T
Other languages
English (en)
Inventor
Nathaniel A Brown
Lynn D Condreay
Douglas Fraser Gray
Marc Rubin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE273012T1 publication Critical patent/ATE273012T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Packages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00971593T 1999-10-29 2000-10-27 Kombinationen von lamivudin und entecavir für behandlung der hepatitis b virus infektion ATE273012T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/429,863 US6432966B2 (en) 1999-10-29 1999-10-29 Antiviral combinations
PCT/GB2000/004137 WO2001030329A2 (en) 1999-10-29 2000-10-27 Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction

Publications (1)

Publication Number Publication Date
ATE273012T1 true ATE273012T1 (de) 2004-08-15

Family

ID=23705033

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00971593T ATE273012T1 (de) 1999-10-29 2000-10-27 Kombinationen von lamivudin und entecavir für behandlung der hepatitis b virus infektion

Country Status (10)

Country Link
US (1) US6432966B2 (de)
EP (1) EP1225904B1 (de)
JP (1) JP2003512421A (de)
AR (1) AR026255A1 (de)
AT (1) ATE273012T1 (de)
AU (1) AU1042701A (de)
DE (1) DE60012961T2 (de)
ES (1) ES2225245T3 (de)
TW (1) TWI282735B (de)
WO (1) WO2001030329A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020649A2 (en) † 2000-02-29 2004-12-31 Bristol Myers Squibb Co Low dose entecavir formulation and use
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
US8168568B1 (en) * 2003-03-10 2012-05-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Combinatorial therapy for protein signaling diseases
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
CN102552210B (zh) * 2012-01-10 2013-12-11 四川海思科制药有限公司 一种恩替卡韦胶囊组合物及其制备方法
WO2016164619A2 (en) * 2015-04-07 2016-10-13 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of hbv infection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9800452D0 (sv) * 1998-02-13 1998-02-13 Medivir Ab Antivirals
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5206244A (en) 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
DE69206876T3 (de) 1991-05-16 2004-08-12 Glaxo Group Ltd., Greenford Nukleosidanalogen enthaltende Antiviren-Zubereitungen
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
EP0988042B1 (de) * 1997-04-15 2008-01-09 Advanced Viral Research Corp. Kombination von product r mit einem antiviralen mittel in der behandlung von hiv infektionen
CN1279610A (zh) * 1997-09-25 2001-01-10 康奈尔研究基金会股份有限公司 抑制肝癌发展和提高慢性肝dna病毒感染者存活率的方法

Also Published As

Publication number Publication date
US6432966B2 (en) 2002-08-13
ES2225245T3 (es) 2005-03-16
WO2001030329A2 (en) 2001-05-03
US20020002180A1 (en) 2002-01-03
AR026255A1 (es) 2003-02-05
AU1042701A (en) 2001-05-08
EP1225904A2 (de) 2002-07-31
EP1225904B1 (de) 2004-08-11
JP2003512421A (ja) 2003-04-02
DE60012961T2 (de) 2005-08-18
DE60012961D1 (de) 2004-09-16
WO2001030329A3 (en) 2001-11-01
TWI282735B (en) 2007-06-21

Similar Documents

Publication Publication Date Title
DE69737793D1 (de) Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs
DE60001421D1 (de) Behandlung von abgas
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
ATE315938T1 (de) 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen
EE05442B1 (et) V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks
DE69836915D1 (de) Mundpflegemittel zur behandlung von übelriechendem atem
DE69835011D1 (de) Unterschiedliche behandlung von prothesenteilen
ATE358418T1 (de) Antimikrobielle vorbeugung gegen und behandlung von aids und anderer infektiöser krankheiten
FI20080432L (fi) L-nukleosidejä hepatiitti-B-viruksen ja Epstein-Barr-viruksen hoitamiseksi
DE60033133D1 (de) Wabenförmiger filter und anordnung von keramischen filtern
AP2001002301A0 (en) Inhibition of viral infection using monovalentantigen-binding proteins
DE60234760D1 (de) Phenylindole zur behandlung von hiv
DE69902223D1 (de) Polyfunktionelle organosilan behandlung von kieselsäure
DE69906848D1 (de) Reinigung und Gewinnung von Acetonitril
EP1117431A4 (de) Behandlung von acidose
EP1416957A4 (de) Behandlung von immunerkrankungen und b-zellen-erkrankungen
DE69810499D1 (de) Behandlung von industriegeweben
ATE273012T1 (de) Kombinationen von lamivudin und entecavir für behandlung der hepatitis b virus infektion
DE60031826D1 (de) Trennung von Viren und Nachweis von Viren
DE69926485D1 (de) Behandlung von durchblasgasen
DE60006412D1 (de) Oxazinochinolone zur behandlung von viralen infektionen
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
DE60103685D1 (de) Behandlung von Poriomania
DE60026821D1 (de) Behandlung von bohrspülung
DE60020583D1 (de) Synchronisierung von pcm und pseudozufallstaktgebern

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties